Abbott (NYSE: ABT) and Facet Biotech Corporation (Nasdaq: FACT) announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline. Abbott will acquire Facet for $27 per share in cash for a net transaction value of approximately $450 million, which includes a purchase price of approximately $722 million less Facet's projected cash and marketable securities at closing of approximately $272 million.
The acquisition brings access to biologics in two key therapeutic areas, immunology and oncology. The compounds include daclizumab – a Phase II investigational biologic intended to treat multiple sclerosis (MS) that is expected to move into Phase III development in the second quarter 2010 – and oncology compounds in early- to mid-stage development ...
This article: 631 words
Date Published: Mar 9, 2010 04:56PM
Why is this preview so short?
StreetInsider.com provides up-to-the-minute active trading news and information. Only the most relevant news makes it through to our members, and only what you need to hear. Our articles are concise and packed with information, so we are only able to provide you with short previews. Join StreetInsider.com today to see the full version of this article and many more like it.
Join StreetInsider.com Today!
The following plans will be available to you:
- Street Insider Premium 30 days - $29.00 .
- Street Insider Premium 90 days - $80.00 .
- Street Insider Premium 180 days - $150.00 .
- Street Insider Premium 360 days - $250.00 .
- Street Insider Premium 14 days - Free .
Get Access to this story and many, many, more.
You can choose to sign up for a Premium Subscription, Free Basic Subscription, or a Free 2-Week Premium Trial!
With StreetInsider Premium, you will have access to fully-categorized, up-to-the-minute news reports from our team of professionals.
Full Feed: Available in an auto-refresh browser window, with the full articles, or in a streaming headline format, which links to the full article, this section will give you all the articles StreetInsider.com publish with the newest article at the top.
Portfolio/Alerts: Set up e-mail alerts by ticker symbol or by category type. When a new article meets your criteria you will get an e-mail alert.
Corporate News: Corporate news issued in the form of a company press release or an SEC filing, which our staff views as important and potentially market moving.
Rumors: The old Wall Street saying,"buy the rumor, sell the news" is alive and well in the fast paced equity markets. We track them down and report them to our members if they come from a reliable source, having an influence on the market, or make some sense.
Insider Trades: Insider buying and selling moves stocks, but not all transactions are created equal. We give you insight on the transactions that are meaningful.
IPOs: We track IPOs before and after they hit the market, and identify upcoming Hot IPOs.
Insiders' Blog: Special comments, insight and stock ideas from our staff
Hot List: The hottest stories of the day as we see them.
And much more, including:Earnings
Guidance
Upgrades
Downgrades
New Coverage
Analyst Comments
Mergers and Acquisitions
Trader Talk
Equity Offerings
Stock Splits
Stock Buybacks
Dividends
FDA
Momentum Movers
Special Reports
General News
Retail Sales
Management Changes
Economic Data
